Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,244,264
  • Shares Outstanding, K 695,492
  • Annual Sales, $ 29,050 K
  • Annual Income, $ -171,980 K
  • EBIT $ -1,197 M
  • EBITDA $ -1,183 M
  • 60-Month Beta 1.22
  • Price/Sales 618.10
  • Price/Cash Flow N/A
  • Price/Book 3.61

Options Overview Details

View History
  • Implied Volatility 59.15% (+2.36%)
  • Historical Volatility 66.34%
  • IV Percentile 90%
  • IV Rank 56.65%
  • IV High 83.81% on 02/05/26
  • IV Low 26.92% on 04/14/25
  • Expected Move (DTE 10) 1.28 (4.68%)
  • Put/Call Vol Ratio 0.73
  • Today's Volume 1,323
  • Volume Avg (30-Day) 3,373
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 56,218
  • Open Int (30-Day) 76,220
  • Expected Range 25.96 to 28.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.42
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -29.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.98 +29.77%
on 02/02/26
27.93 -2.52%
on 02/10/26
+5.25 (+23.86%)
since 01/09/26
3-Month
19.96 +36.40%
on 12/02/25
27.93 -2.52%
on 02/10/26
+6.06 (+28.60%)
since 11/10/25
52-Week
8.73 +211.86%
on 04/07/25
27.93 -2.52%
on 02/10/26
+16.44 (+152.32%)
since 02/10/25

Most Recent Stories

More News
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P

ROIVW : 2.75 (-3.85%)
ROIV : 27.35 (-1.16%)
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P

ROIVW : 2.75 (-3.85%)
ROIV : 27.35 (-1.16%)
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide...

IMVT : 26.68 (-2.95%)
ROIV : 27.35 (-1.16%)
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February...

ROIVW : 2.75 (-3.85%)
ROIV : 27.35 (-1.16%)
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three years Highlighting clinical execution,...

ROIVW : 2.75 (-3.85%)
ROIV : 27.35 (-1.16%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 19.55 (+6.02%)
GTBP : 0.5153 (+6.95%)
ROIV : 27.35 (-1.16%)
CCCC : 1.8400 (+3.37%)
BMY : 60.86 (+0.15%)
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided...

ROIVW : 2.75 (-3.85%)
ROIV : 27.35 (-1.16%)
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business...

IMVT : 26.68 (-2.95%)
ROIV : 27.35 (-1.16%)
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November...

ROIVW : 2.75 (-3.85%)
ROIV : 27.35 (-1.16%)
This Red-Hot Biopharma Stock Could Fizzle Out Soon

Roivant Sciences (ROIV) shows strong technical momentum and is trading at new all-time highs. Shares are up 52% over the past year and 20% in the last month. ROIV has a 100% “Buy” opinion from Barchart...

ROIV : 27.35 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 30.35
2nd Resistance Point 29.04
1st Resistance Point 28.35
Last Price 27.35
1st Support Level 26.35
2nd Support Level 25.04
3rd Support Level 24.35

See More

52-Week High 27.93
Last Price 27.35
Fibonacci 61.8% 20.60
Fibonacci 50% 18.33
Fibonacci 38.2% 16.06
52-Week Low 8.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar